{"url_path":"/sec/sptx/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-06-08","source_url":"https://www.sec.gov/Archives/edgar/data/2042347/0001193125-26-260678-index.html","accession_number":"0001193125-26-260678","cik":"0002042347","ticker":"SPTX","issuer_name":"Seaport Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2042347/0001193125-26-260678-index.html","primary_entity_key":"0002042347","primary_entity_name":"Seaport Therapeutics, Inc."},"word_count":798,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\nFurnish the exhibits required by Item 601 of Regulation S-K (§ 229.601 of this chapter).\n\n \n\nExhibit\n\nNumber\n\nDescription\n\n[3.1](https://www.sec.gov/Archives/edgar/data/2042347/000119312526204086/d150068dex31.htm)\n\n \n\nAmended and Restated Certificate of Incorporation (as currently in effect) (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-43254)).\n\n[3.2](https://www.sec.gov/Archives/edgar/data/2042347/000119312526204086/d150068dex32.htm)\n\n \n\nAmended and Restated Bylaws of Seaport Therapeutics, Inc (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-43254).\n\n[4.1](https://www.sec.gov/Archives/edgar/data/2042347/000119312526151211/d73463dex42.htm)†+\n\n \n\n \n\nAmended and Restated Investors’ Rights Agreement, by and between the Registrant and certain of its stockholders, dated as of October 18, 2024 (incorporated by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-294976).\n\n[4.2](https://www.sec.gov/Archives/edgar/data/2042347/000119312526151211/d73463dex41.htm)\n\n \n\nSpecimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registrant's Registration Statement on Form S-1 (File No. 333-294976).\n\n[10.1](https://www.sec.gov/Archives/edgar/data/2042347/000119312526178716/d73463dex102.htm)#\n\n \n\n \n\n2026 Equity Incentive Plan and form of award agreements thereunder (incorporated by reference to Exhibit 10.2 to the Registrant's Registration Statement on Form S-1 (File No. 333-294976).\n\n[10.2](https://www.sec.gov/Archives/edgar/data/2042347/000119312526178716/d73463dex103.htm)#\n\n \n\n2026 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.3 to the Registrant's Registration Statement on Form S-1 (File No. 333-294976).\n\n[10.3](https://www.sec.gov/Archives/edgar/data/2042347/000119312526151211/d73463dex104.htm)#\n\n \n\nForm of Officer Indemnification Agreement, by and between the Registrant and executive officers (incorporated by reference to Exhibit 10.4 to the Registrant’s Registration Statement on Form S-1 (File No. 333-294976).\n\n[10.4](https://www.sec.gov/Archives/edgar/data/2042347/000119312526151211/d73463dex105.htm)#\n\n \n\nForm of Director Indemnification Agreement, by and between the Registrant and its directors (incorporated by reference to Exhibit 10.5 to the Registrant’s Registration Statement on Form S-1 (File No. 333-294976).\n\n[10.5](https://www.sec.gov/Archives/edgar/data/2042347/000119312526151211/d73463dex106.htm)#\n\n \n\n \n\nSenior Executive Cash Incentive Bonus Plan (incorporated by reference to Exhibit 10.6 to the Registrant’s Registration Statement on Form S-1 (File No. 333-294976).\n\n[10.6](https://www.sec.gov/Archives/edgar/data/2042347/000119312526151211/d73463dex107.htm)#\n\n \n\n \n\nExecutive Severance Plan (incorporated by reference to Exhibit 10.7 to the Registrant’s Registration Statement on Form S-1 (File No. 333-294976).\n\n[10.7](https://www.sec.gov/Archives/edgar/data/2042347/000119312526151211/d73463dex108.htm)#\n\n \n\n \n\nNon-Employee Director Compensation Policy (incorporated by reference to Exhibit 10.8 to the Registrant’s Registration Statement on Form S-1 (File No. 333-294976).\n\n[10.8](https://www.sec.gov/Archives/edgar/data/2042347/000119312526151211/d73463dex109.htm)#\n\n \n\n \n\nCompensation Recovery Policy (incorporated by reference to Exhibit 10.9 to the Registrant’s Registration Statement on Form S-1 (File No. 333-294976).\n\n[10.9](https://www.sec.gov/Archives/edgar/data/2042347/000119312526151211/d73463dex1014.htm)†+\n\n \n\n \n\nAsset Transfer Agreement, by and between the Registrant, PureTech Health LLC and PureTech LYT, Inc., dated April 8, 2024, as amended by that certain amendment, dated December 16, 2025 (incorporated by reference to Exhibit 10.14 to the Registrant’s Registration Statement on Form S-1 (File No. 333-294976).\n\n[10.10](https://www.sec.gov/Archives/edgar/data/2042347/000119312526151211/d73463dex1015.htm)†+\n\n \n\n \n\nAmended and Restated License Agreement between Monash University, ABN 12 377 614 012, a body politic and corporate constituted in accordance with the Monash University Act 2009 of Wellington Road, Clayton, Victoria, Australia 3800 and the Registrant, dated March 12, 2025 (incorporated by reference to Exhibit 10.15 to the Registrant’s Registration Statement on Form S-1 (File No. 333-294976).\n\n[31.1](sptx-ex31_1.htm)*\n\nCertification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.\n\n[31.2](sptx-ex31_2.htm)*\n\nCertification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.\n\n[32.1](sptx-ex32_1.htm)**\n\nCertification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.\n\n[32.2](sptx-ex32_2.htm)**\n\nCertification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.\n\n101.INS*\n\nInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.\n\n101.SCH*\n\n \n\nInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents\n\n104*\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n* Filed herewith.\n\n** The certifications furnished in Exhibit 32.1 and 32.2 hereto are deemed to be furnished with this Quarterly Report and will not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, except to the extent that the Registrant specifically incorporates it by reference.\n\n#\n\nIndicates a management contract or any compensatory plan, contract or arrangement.\n\n†\n\nCertain portions of this document that constitute confidential information have been redacted pursuant to Item 601(b)(10) of Regulation S-K.\n\n \n\n+\n\nCertain exhibits and schedules to these agreements have been omitted pursuant to Item 601(a)(5) and (6) of Regulation S-K. The registrant will furnish copies of any of the exhibits and schedules to the Securities and Exchange Commission upon request.\n\n \n\n101\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\n \n\nSeaport Therapeutics, Inc.\n\n \n\n \n\n \n\n \n\nDate: June 8, 2026\n\n \n\nBy:\n\n/s/ Daphne Zohar\n\n \n\n \n\n \n\nDaphne Zohar\n\n \n\n \n\n \n\nChief Executive Officer and Director\n\n \n\n \n\n \n\n(Principal Executive Officer)\n\n \n\n \n\n \n\n \n\nDate: June 8, 2026\n\n \n\nBy:\n\n/s/ Lauren White\n\n \n\n \n\n \n\nLauren A. White\n\n \n\n \n\n \n\nChief Financial Officer\n\n \n\n \n\n \n\n(Principal Financial Officer and Principal\n\n \n\n \n\n \n\nAccounting Officer)\n\n \n\n102"}